MiniMed Stock Upgrade Rally
MiniMed Stock Hits 52-Week High Following Analyst Upgrades and Strong Revenue
Anonymous
Key Points
1
Citigroup raised its MiniMed Group price target to 26 (from 23), and the stock touched a new 52-week intraday high (as high as about $21.86), signaling renewed upside conviction.
2
A wave of upgrades and coverage initiations from multiple firms supported a more positive stance: Mizuho lifted its target to 26 with an Outperform rating; UBS started coverage with a Buy at 25; BTIG raised its target to 28; Bank of America increased its target to 28.
3
Bank of America trimmed its price target to 20 from 27 but kept a Buy rating, contrasting with several peers raising targets.
4
In its latest quarter, MMED reported about $843 million in net sales for Q1 2027, up 17% year over year, with U.S. organic growth at 13% and international sales up 18%, and it raised its FY organic revenue-growth guidance.
5
Management highlighted additional regulatory milestones underway, including an FDA submission for MiniMed Fit, CE Mark approval for MiniMed Flex, completion of the Vivera FCL U.S. pivotal trial enrollment, and IDE approval for a next-generation device.
MiniMed Group's stock hit a new 52-week high this week after a wave of analyst upgrades and strong quarterly results. Citigroup raised its price target to $26, while Mizuho, UBS, BTIG, and Bank of America also lifted their targets or initiated positive coverage. The company reported $843 million in quarterly revenue, up 17% year over year, beating expectations and prompting the buying spree.
Analyst Upgrades Push Stock Toward $26 Target
The rally gained momentum as major firms turned bullish on the diabetes-care company. Mizuho assigned an Outperform rating with a $26 target, matching Citigroup's move. BTIG went furthest, setting a $28 target. UBS entered the picture with a Buy rating and $25 target. MarketBeat now pegs the consensus target at roughly $23.62, suggesting the stock has further room to run from recent levels near $21.86.
First-Quarter Sales Growth Crushes Expectations
MiniMed posted $843 million in net sales for Q1 2027, crushing the 17% year-over-year growth benchmark. U.S. organic revenue grew 13%, while international markets surged 18%. The company raised its full-year organic revenue guidance, signaling confidence in sustained momentum. AOL and Yahoo Finance both highlighted the earnings beat as the catalyst for this week's 19% stock surge.
Pipeline Progress and Regulatory Wins Fuel Optimism
Management disclosed several upcoming milestones that impressed investors. The company filed for FDA approval of MiniMed Fit, achieved CE Mark clearance for MiniMed Flex, and completed enrollment in the Vivera FCL U.S. trial. An IDE approval for a next-generation device rounds out the roadmap. These regulatory wins suggest the company can maintain growth momentum through 2027 and beyond.
Valuation Remains a Key Question for Growth Story
Despite the bullish sentiment, investors remain focused on whether MiniMed can sustain high growth while improving profitability. Simply Wall Street notes the stock trades below fair value on standard metrics, yet the elevated earnings multiple reflects market skepticism about profitability timing. The company's 2026 spin-off from Medtronic left it independent but carrying ambitious expectations. Analysts see the next two quarters as crucial for proving the growth thesis is real.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
28
Reach
42
A
AnonymousAuthor
